Business Daily from THE HINDU group of publications
Saturday, Nov 25, 2006

Cross Currency

Group Sites

Corporate - Regulatory Bodies & Rulings
Zydus files application for obesity drug

Our Bureau

Mumbai, Nov. 24

Zydus Cadila has filed an Investigational New Drug (IND) application with the Drug Controller General of India for the new molecular entity — ZY01, a drug candidate for treating obesity and related disorders.

ZYO1 is an experimental drug to help obese patients lose weight and control blood sugar levels in type-2 diabetes.

"ZYO1 has shown remarkable efficacy and a clean toxicity profile in pre-clinical trials. It holds promising commercial potential in the absence of effective treatments for obesity and related disorders," said Mr Pankaj Patel, Chairman and Managing Director of Zydus Cadila. Zydus Cadila plans to initiate clinical trials to ensure the safety and tolerability of ZYO1.

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Essar Oil starts trial runs at Vadinar refinery

UniverCell plans to raise Rs 100 cr
Assam Co raises $46 m
Sundram Fasteners to pay 85% interim
India Inc: The new turnaround specialist on the block
Tata Steel dubs media reports speculative
SAB Miller plans capacity expansion
Ford's new diesel engine plant may serve as outsourcing hub
Haldia Petrochem to go ahead with naphtha cracker unit plan
Jupiter Bio plans to raise Rs 95 cr
Zydus files application for obesity drug
Madura Garments in pact with Sierra for footwear
Kovilpatti Lakshmi forays into metal manufacturing
Honda Motorcycle plans export-push for bike models
DaimlerChrysler expects to sell 2,000 cars in current year
NTPC to spend Rs 6,000 cr on coal block

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line